Loading
Biomarkers / Alzheimer Disease / Alzheimer’s Disease · Journal article
Dialogues in Clinical Neuroscience · February 6, 2026
A consensus or society position rather than new primary data.
This narrative review aims to synthesize potential biomarkers for diagnosis, progression, prognosis and therapeutic monitoring in Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. The provided text contains only the introduction and does not present the actual biomarker findings or evidence synthesis.
Narrative literature review. Patients with Alzheimer's disease, Parkinson's disease, or amyotrophic lateral sclerosis.
AD affects approximately 5.8 million individuals in United States AD prevalence surges to nearly 30% among adults aged 85 or older PD affects approximately 1 million individuals in United States
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The review intends to provide guidance on biomarkers for blood, cerebrospinal fluid, neuroimaging and emerging non-invasive indicators to improve early diagnosis, progression monitoring and therapeutic evaluation. However, the truncated text does not permit assessment of the actual evidence or recommendations presented.
This is a narrative literature review synthesizing current evidence on biomarkers for neurodegenerative diseases without presenting primary data or meta-analytic findings.
As stated by the source record.
Quoted from the source exactly as published.
The review intends to provide guidance on biomarkers for blood, cerebrospinal fluid, neuroimaging and emerging non-invasive indicators to improve early diagnosis, progression monitoring and therapeutic evaluation. However, the truncated text does not permit assessment of the actual evidence or recommendations presented.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Introduction. Alzheimer's disease (AD), Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS) are several common neurodegenerative diseases (NDs). At present, is the lack of effective diagnosis, progression, prognosis and therapeutic biomarkers. it is a urgent demand to search the relevant confident biomarkers.Area covered. This review systematically analysed the potential biomarkers of blood, cerebrospinal fluid, neuroimaing and emerging non-invasive indicators, and synthesises current evidences on the biomarkers of AD, PD and ALS about diagnosis, progression, prognosis and therapeutic, especially diagnosis biomarkers.Expert commentary. In this review, we focus on discussing relevant diagnosis, progression, prognosis and therapeutic biomarkers for AD, PD and ALS in recent years, and prospecting the possible future directions of relevant biomarkers.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.